Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | PPID | Q08752 | 1/20 | 0.34 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | CAD | P27708 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18452348 | 1.00 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL29465612 | 1.00 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL20465440 | 0.97 | CTSL (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL18452352 | 0.97 | CTSL (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL18451208 | 0.88 | CTSL (0.32) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20465427 | 0.88 | CTSL (0.32) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20468520 | 0.88 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL20465422 | 0.88 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1METAP2 | |
| SCHEMBL18451341 | 0.88 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1METAP2 | |
| SCHEMBL30919316 | 0.88 | NOD1 (0.38) | L3MBTL1KMT2APOLBNOD1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121320099-B | Toxoplasma gondii in-vitro merozoite induction model and construction method thereof | 南方医科大学 | 2026-03-13 | — | — | CN | disclosed |
| CN-121405665-A | 6-Diazonium-5-oxo-norleucine prodrug as well as preparation method and application thereof | 西北工业大学深圳研究院 | 2026-01-27 | — | — | CN | disclosed |
| CN-121320099-A | Toxoplasma gondii in-vitro merozoite induction model and construction method thereof | 南方医科大学 | 2026-01-13 | — | — | CN | disclosed |
| EP-4097119-B1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | UNIV JOHNS HOPKINS (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119912442-A | 2, 4-Disubstituted thiadiazole derivatives and their use as GLS1 inhibitors | 四川大学华西医院 | 2025-05-02 | — | — | CN | disclosed |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20230374593-A1 | PKD MUTATIONS AND EVALUATION OF SAME | ATHENA DIAGNOSTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-114621120-B | DON prodrug molecule, prodrug activating compound and prodrug activating system | 深圳先进技术研究院 | 2023-11-03 | — | — | CN | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11655508-B2 | PKD mutations and evaluation of same | ATHENA DIAGNOSTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2023085771-A1 | ANTICANCER COMPOSITION COMPRISING METABOLIC ANTICANCER DRUG | 주식회사 노암 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4097119-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | The Johns Hopkins University (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114621120-A | DON prodrug molecule, prodrug activation compound and prodrug activation system | 深圳先进技术研究院 | 2022-06-14 | — | — | CN | disclosed |
| CN-113461563-B | NQO1 activated 6-diazo-5-oxo-L-norleucine prodrug and preparation method and application thereof | 中国药科大学 | 2022-05-10 | — | — | CN | disclosed |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | L3MBTL1 198/4885KMT2A 1198/4885POLB 2768/4885 |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | L3MBTL1 742/4885KMT2A 1078/4885POLB 1442/4885 |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | L3MBTL1 4481/4885KMT2A 2142/4885POLB 2045/4885 |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | GLS, GLS2, PC | L3MBTL1 1184/4885KMT2A 1383/4885POLB 717/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | GLS, GLUL, ASNS | L3MBTL1 898/4885KMT2A 1775/4885POLB 3384/4885 |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | ADORA2A, ADORA1, ADORA2B | L3MBTL1 742/4885KMT2A 1078/4885POLB 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.